Literature DB >> 19933495

Regulation of SIV mac 239 basal long terminal repeat activity and viral replication in macrophages: functional roles of two CCAAT/enhancer-binding protein beta sites in activation and interferon beta-mediated suppression.

Shruthi Ravimohan1, Lucio Gama, Sheila A Barber, Janice E Clements.   

Abstract

CCAAT/enhancer-binding protein (C/EBP) beta and C/EBP sites in the HIV-1 long terminal repeat (LTR) are crucial for HIV-1 replication in monocyte/macrophages and for the ability of interferon beta (IFN beta) to inhibit ongoing active HIV replication in these cells. This IFN beta-mediated down-regulation involves induction of the truncated, dominant-negative isoform of C/EBP beta referred to as liver-enriched transcriptional inhibitory protein (LIP). Although binding of the C/EBP beta isoform to C/EBP sites in the simian immunodeficiency virus (SIV) LTR has previously been examined, the importance of these sites in core promoter-mediated transcription, virus replication, IFN beta-mediated regulation, and the relative binding of the two isoforms (C/EBP beta and LIP) has not been investigated. Here, we specifically examine two C/EBP sites, JC1 (-100 bp) and DS1 (+134 bp), located within the minimal region of the SIV LTR, required for core promoter-mediated transcription and virus replication in macrophages. Our studies revealed that the JC1 but not DS1 C/EBP site is important for basal level transcription, whereas the DS1 C/EBP site is imperative for productive virus replication in primary macrophages. In contrast, either JC1 or DS1 C/EBP site is sufficient to mediate IFN beta-induced down-regulation of SIV LTR activity and virus replication in these cells. We also characterized the differential binding properties of C/EBP beta and LIP to the JC1 and DS1 sites. In conjunction with previous studies from our laboratory, we demonstrate the importance of these sites in virus gene expression, and we propose a model for their role in establishing latency and persistence in macrophages in the brain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19933495      PMCID: PMC2807283          DOI: 10.1074/jbc.M109.075929

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  75 in total

1.  Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir.

Authors:  S Kravcik; K Gallicano; V Roth; S Cassol; N Hawley-Foss; A Badley; D W Cameron
Journal:  J Acquir Immune Defic Syndr       Date:  1999-08-15       Impact factor: 3.731

2.  Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine.

Authors:  N A Foudraine; R M Hoetelmans; J M Lange; F de Wolf; B H van Benthem; J J Maas; I P Keet; P Portegies
Journal:  Lancet       Date:  1998-05-23       Impact factor: 79.321

3.  Phosphorylation and proteolytic cleavage of gag proteins in budded simian immunodeficiency virus.

Authors:  Sarah M Rue; Jason W Roos; Patrick M Tarwater; Janice E Clements; Sheila A Barber
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

4.  Cooperative interaction of C/EBP beta and Tat modulates MCP-1 gene transcription in astrocytes.

Authors:  Selvajothi Abraham; Thersa Sweet; Bassel E Sawaya; Jay Rappaport; Kamel Khalili; Shohreh Amini
Journal:  J Neuroimmunol       Date:  2005-01-26       Impact factor: 3.478

5.  A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA.

Authors:  P Wei; M E Garber; S M Fang; W H Fischer; K A Jones
Journal:  Cell       Date:  1998-02-20       Impact factor: 41.582

6.  The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.

Authors:  R B Kim; M F Fromm; C Wandel; B Leake; A J Wood; D M Roden; G R Wilkinson
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

7.  Physical interaction and mutual transrepression between CCAAT/enhancer-binding protein beta and the p53 tumor suppressor.

Authors:  Tanja Schneider-Merck; Yvonne Pohnke; Rita Kempf; Mark Christian; Jan J Brosens; Birgit Gellersen
Journal:  J Biol Chem       Date:  2005-10-14       Impact factor: 5.157

8.  Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1--infected patients with and without AIDS dementia complex.

Authors:  F Aweeka; A Jayewardene; S Staprans; S E Bellibas; B Kearney; P Lizak; T Novakovic-Agopian; R W Price
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1999-01-01

9.  Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity.

Authors:  Gang Peng; Ke Jian Lei; Wenwen Jin; Teresa Greenwell-Wild; Sharon M Wahl
Journal:  J Exp Med       Date:  2006-01-17       Impact factor: 14.307

10.  Type I interferon induces inhibitory 16-kD CCAAT/ enhancer binding protein (C/EBP)beta, repressing the HIV-1 long terminal repeat in macrophages: pulmonary tuberculosis alters C/EBP expression, enhancing HIV-1 replication.

Authors:  Y Honda; L Rogers; K Nakata; B Y Zhao; R Pine; Y Nakai; K Kurosu; W N Rom; M Weiden
Journal:  J Exp Med       Date:  1998-10-05       Impact factor: 14.307

View more
  5 in total

Review 1.  Illuminating viral infections in the nervous system.

Authors:  Dorian B McGavern; Silvia S Kang
Journal:  Nat Rev Immunol       Date:  2011-05       Impact factor: 53.106

2.  RON receptor tyrosine kinase, a negative regulator of inflammation, is decreased during simian immunodeficiency virus-associated central nervous system disease.

Authors:  Daniele C Cary; Janice E Clements; Andrew J Henderson
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

3.  Brain macrophages harbor latent, infectious simian immunodeficiency virus.

Authors:  Celina Abreu; Erin N Shirk; Suzanne E Queen; Sarah E Beck; Lisa M Mangus; Kelly A M Pate; Joseph L Mankowski; Lucio Gama; Janice E Clements
Journal:  AIDS       Date:  2019-12-01       Impact factor: 4.177

4.  Early emergence and selection of a SIV-LTR C/EBP site variant in SIV-infected macaques that increases virus infectivity.

Authors:  Shruthi Ravimohan; Lucio Gama; Elizabeth L Engle; M Christine Zink; Janice E Clements
Journal:  PLoS One       Date:  2012-08-27       Impact factor: 3.240

5.  Relative resistance of HIV-1 founder viruses to control by interferon-alpha.

Authors:  Angharad E Fenton-May; Oliver Dibben; Tanja Emmerich; Haitao Ding; Katja Pfafferott; Marlen M Aasa-Chapman; Pierre Pellegrino; Ian Williams; Myron S Cohen; Feng Gao; George M Shaw; Beatrice H Hahn; Christina Ochsenbauer; John C Kappes; Persephone Borrow
Journal:  Retrovirology       Date:  2013-12-03       Impact factor: 4.602

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.